Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy

被引：42

作者：

Awasthi, Rakesh ^{[1
,5
]}

Maier, Harald J. ^{[2
]}

Zhang, Jie ^{[3
]}

Lim, Stephen ^{[4
]}

机构：

[1] Novartis Inst Biomed Res, E Hanover, NJ USA

[2] Novartis Pharm AG, Oncol & Hematol, Global Drug Dev, Basel, Switzerland

[3] Novartis Serv Inc, Cell & Gene Unit, E Hanover, NJ USA

[4] Novartis Pharmaceut, US Med Affairs, Oncol, E Hanover, NJ USA

[5] Novartis Inst Biomed Res, Oncol & Hematol, One Hlth Plaza, E Hanover, NJ 07936 USA

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2023年 / 19卷 / 01期

关键词：

Cell and gene therapy; CAR-T therapy; clinical development; immunotherapy; leukemia; lymphoma; B-CELL LYMPHOMA; UNITED-STATES; OUTCOMES; JULIET; MANAGEMENT; 2ND-LINE;

D O I：

10.1080/21645515.2023.2210046

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The emergence of cell and gene therapies has dramatically changed the treatment paradigm in oncology and other therapeutic areas. Kymriah (R) (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, is currently approved in major markets for the treatment of relapsed/refractory (r/r) pediatric and young adult acute lymphoblastic leukemia, r/r diffuse large B-cell lymphoma, and r/r follicular lymphoma. This article presents a high-level overview of the clinical development journey of tisagenlecleucel, including its efficacy outcomes and safety considerations.

引用

页数：8

共 47 条

[31] Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia [J].

Pulsipher, Michael A. ;

Han, Xia ;

Maude, Shannon L. ;

Laetsch, Theodore W. ;

Qayed, Muna ;

Rives, Susana ;

Boyer, Michael W. ;

Hiramatsu, Hidefumi ;

Yanik, Gregory A. ;

Driscoll, Tim ;

Myers, G. Doug ;

Bader, Peter ;

Baruchel, Andre ;

Buechner, Jochen ;

Stefanski, Heather E. ;

Kalfoglou, Creton ;

Nguyen, Kevin ;

Waldron, Edward R. ;

Mueller, Karen Thudium ;

Maier, Harald J. ;

Kari, Gabor ;

Grupp, Stephan A. .

BLOOD CANCER DISCOVERY, 2022, 3 (01) :66-81

[32] Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas [J].

Riedell, Peter A. ;

Hwang, Wei-Ting ;

Nastoupil, Loretta J. ;

Pennisi, Martina ;

McGuirk, Joseph P. ;

Maziarz, Richard T. ;

Bachanova, Veronika ;

Oluwole, Olalekan O. ;

Brower, Jamie ;

Flores, Oscar A. ;

Ahmed, Nausheen ;

Schachter, Levanto ;

Bharucha, Kharmen ;

Dholaria, Bhagirathbhai R. ;

Schuster, Stephen J. ;

Perales, Miguel-Angel ;

Bishop, Michael R. ;

Porter, David L. .

TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (10) :669-676

[33]

Rives S., 2022, HemaSphere, V6, P13

[34] CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How? [J].

Roschewski, Mark ;

Longo, Dan L. ;

Wilson, Wyndham H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07) :692-696

[35] Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States [J].

Roth, Joshua A. ;

Sulliyan, Sean D. ;

Lin, Vincent W. ;

Bansal, Aasthaa ;

Purdum, Anna G. ;

Nayale, Lynn ;

Cheng, Paul ;

Ramsey, Scott D. .

JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (12) :1238-1245

[36] Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline [J].

Santomasso, Bianca D. ;

Nastoupil, Loretta J. ;

Adkins, Sherry ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Anadkat, Milan ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Davies, Marianne J. ;

Ernstoff, Marc S. ;

Fecher, Leslie ;

Funchain, Pauline ;

Jaiyesimi, Ishmael ;

Mammen, Jennifer S. ;

Naidoo, Jarushka ;

Naing, Aung ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Reichner, Cristina A. ;

Seigel, Carole ;

Song, Jung-Min ;

Spira, Alexander ;

Suarez-Almazor, Maria ;

Swami, Umang ;

Thompson, John A. ;

Vikas, Praveen ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Bollin, Kathryn ;

Ghosh, Monalisa .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (35) :3978-+

[37] Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report [J].

Schultz, Liora M. ;

Baggott, Christina ;

Prabhu, Snehit ;

Pacenta, Holly L. ;

Phillips, Christine L. ;

Rossoff, Jenna ;

Stefanski, Heather E. ;

Talano, Julie-An ;

Moskop, Amy ;

Margossian, Steven P. ;

Verneris, Michael R. ;

Myers, Gary Douglas ;

Karras, Nicole A. ;

Brown, Patrick A. ;

Qayed, Muna ;

Hermiston, Michelle ;

Satwani, Prakash ;

Krupski, Christa ;

Keating, Amy K. ;

Wilcox, Rachel ;

Rabik, Cara A. ;

Fabrizio, Vanessa A. ;

Rouce, Rayne H. ;

Chinnabhandar, Vasant ;

Kunicki, Michael ;

Barsan, Valentin V. ;

Goksenin, A. Yasemin ;

Li, Yimei ;

Mavroukakis, Sharon ;

Egeler, Emily ;

Curran, Kevin J. ;

Mackall, Crystal L. ;

Laetsch, Theodore W. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (09) :945-955

[38] Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study [J].

Schuster, Stephen J. ;

Tam, Constantine S. ;

Borchmann, Peter ;

Worel, Nina ;

McGuirk, Joseph P. ;

Holte, Harald ;

Waller, Edmund K. ;

Jaglowski, Samantha ;

Bishop, Michael R. ;

Damon, Lloyd E. ;

Foley, Stephen Ronan ;

Westin, Jason R. ;

Fleury, Isabelle ;

Ho, P. Joy ;

Mielke, Stephan ;

Teshima, Takanori ;

Janakiram, Murali ;

Hsu, Jing-Mei ;

Izutsu, Koji ;

Kersten, Marie Jose ;

Ghosh, Monalisa ;

Wagner-Johnston, Nina ;

Kato, Koji ;

Corradini, Paolo ;

Martinez-Prieto, Marcela ;

Han, Xia ;

Tiwari, Ranjan ;

Salles, Gilles ;

Maziarz, Richard T. .

LANCET ONCOLOGY, 2021, 22 (10) :1403-1415

[39] Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial [J].

Schuster, Stephen J. ;

Maziarz, Richard T. ;

Rusch, Elisha S. ;

Li, Junlong ;

Signorovitch, James E. ;

Romanov, Vadim V. ;

Locke, Frederick L. ;

Maloney, David G. .

BLOOD ADVANCES, 2020, 4 (07) :1432-1439

[40] Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma [J].

Schuster, Stephen J. ;

Bishop, Michael R. ;

Tam, Constantine S. ;

Waller, Edmund K. ;

Borchmann, Peter ;

McGuirk, Joseph P. ;

Jaeger, Ulrich ;

Jaglowski, Samantha ;

Andreadis, Charalambos ;

Westin, Jason R. ;

Fleury, Isabelle ;

Bachanova, Veronika ;

Foley, S. Ronan ;

Ho, P. Joy p ;

Mielke, Stephan ;

Magenau, John M. ;

Holte, Harald ;

Pantano, Serafino ;

Pacaud, Lida B. ;

Awasthi, Rakesh ;

Chu, Jufen ;

Anak, Ozlem ;

Salles, Gilles ;

Maziarz, Richard T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (01) :45-56

← 1 2 3 4 5 →